imc@healthandcommerce.com, Author at Corcept Therapeutics - Page 5 of 16

About imc@healthandcommerce.com

This author has not written his bio yet.
But we are proud to say that imc@healthandcommerce.com contributed 159 entries already.

Entries by imc@healthandcommerce.com

Miricorilant reduced liver fat and cardiometabolic disease markers in a phase 1b, open-label dose-finding study in patients with non-alcoholic steatohepatitis (NASH)

Alkhouri et al. • 2023 • AASLD 2023 Congress

November 13, 2023

ROSELLA (GOG-3073, ENGOT-OV72/MITO): A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Platinum-Resistant Ovarian Cancer

Lorusso et al. • 2023 • IGCS 2023 Congress

November 6, 2023

Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers

Donaldson et al. • 2023 • NEALS 22nd Annual Meeting

October 6, 2023

ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer

Lorusso et al. • 2023 • ESGO 2023 Congress

October 2, 2023

Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers

Donaldson et al. • 2023 • ENCALS Meeting 2023

July 13, 2023

Hypercortisolism (Cushing syndrome)

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

Simeoli et al. • 2023 • Italian Society of Endocrinology National Congress 2023

July 6, 2023

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Colombo et al. • 2023 • Journal of Clinical Oncology

June 27, 2023

Hypercortisolism (Cushing syndrome)

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

Simeoli et al. • 2023 • ENDO 2023

June 20, 2023

Hypercortisolism (Cushing syndrome)

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

Frias et al. • 2023 • ENDO 2023

June 16, 2023

Hypercortisolism (Cushing syndrome)

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

Frias et al. • 2023 • 7th annual Heart in Diabetes CME Conference

June 9, 2023